Single-cell mapping of combinatorial target antigens for CAR switches using logic gates

Science & Nature

Data availability

The list of cell surface proteins was obtained from the in silico human surfaceome database at http://wlab.ethz.ch/surfaceome/ (ref. 23). The tumor-normal single-cell meta-atlas is available at https://cellatlas.kaist.ac.kr/cart. Raw and processed datasets used in this study are deposited at the Zenodo repository (https://doi.org/10.5281/zenodo.7416669)50. Ovarian cancer single-cell transcriptome data generated in this work are available on the Gene Expression Omnibus with accession number GSE192898 (ref. 51). Source data are provided with this paper.

Code availability

Source codes for CAR target antigen identification, named PCASA (prioritization of combinatorial cancer-associated surface antigens), are available on GitHub at https://github.com/kaistomics/PCASA (ref. 52).

References

  1. Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  2. Marofi, F. et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res. Ther. 12, 81 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  3. Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  4. Fan, J. et al. Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Res. 28, 1217–1227 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  5. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  6. Gao, R. et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 39, 599–608 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  7. Pasquini, G., Rojo Arias, J. E., Schäfer, P. & Busskamp, V. Automated methods for cell type annotation on scRNA-seq data. Comput. Struct. Biotechnol. J. 19, 961–969 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  8. Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  9. Jing, Y. et al. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell 39, 1558–1559 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  10. Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059–1070 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  11. Hege, K. M. et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J. Immunother. Cancer 5, 22 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  12. Yang, Y. et al. Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior antitumor responses. Cancer Immunol. Res. 9, 1158–1174 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  13. Davies, D. M. & Maher, J. Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity? Transl. Cancer Res. 5, S61–S65 (2016).

    Article 
    CAS 

    Google Scholar
     

  14. Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  15. Han, X., Wang, Y., Wei, J. & Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 12, 128 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  16. Hu, Z. et al. The cancer surfaceome atlas integrates genomic, functional and drug response data to identify actionable targets. Nat. Cancer 2, 1406–1422 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  17. Orentas, R. J. et al. Paired expression analysis of tumor cell surface antigens. Front .Oncol. 7, 173 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  18. MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233–244 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  19. Dannenfelser, R. et al. Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst. 11, 215–228 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  20. Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  21. Hie, B., Cho, H., DeMeo, B., Bryson, B. & Berger, B. Geometric sketching compactly summarizes the single-cell transcriptomic landscape. Cell Syst 8, 483–493 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  22. Park, J. E. et al. A cell atlas of human thymic development defines T cell repertoire formation. Science 367, eaay3224 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  23. Bausch-Fluck, D. et al. The in silico human surfaceome. Proc. Natl Acad. Sci. USA 115, E10988–E10997 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  24. Selvaraju, R. R. et al. Grad-CAM: visual explanations from deep networks via gradient-based localization. Proc. IEEE International Conference on Computer Vision https://ieeexplore.ieee.org/document/8237336 (2017).

  25. Chattopadhay, A., Sarkar, A., Howlader, P. & Balasubramanian, V. N. Grad-CAM++: generalized gradient-based visual explanations for deep convolutional networks. in: 2018 IEEE Winter Conference on Applications of Computer Vision (WACV). https://doi.org/10.1109/WACV.2018.00097 (2018).

  26. Cancer Genome Atlas Research Networket al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).

    Article 
    PubMed Central 

    Google Scholar
     

  27. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).

    Article 
    CAS 

    Google Scholar
     

  28. Stoeckius, M. et al. Simultaneous epitope and transcriptome measurement in single cells. Nat. Methods 14, 865–868 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  29. Nakamura, K. et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol. Rep. 37, 3189–3200 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  30. Yang, S. et al. Decontamination of ambient RNA in single-cell RNA-seq with DecontX. Genome Biol. 21, 57 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  31. Tiernan, J. P. et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br. J. Cancer 108, 662–667 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  32. Zhang, J. et al. Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP–WT1–TBL1 axis. Gut 65, 1482–1493 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  33. Kharchenko, P. V., Silberstein, L. & Scadden, D. T. Bayesian approach to single-cell differential expression analysis. Nat. Methods 11, 740–742 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  34. Qiu, P. Embracing the dropouts in single-cell RNA-seq analysis. Nat. Commun. 11, 1169 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  35. Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  36. T, S. et al. Comprehensive integration of single-cell data. Cell 177, 1888–1902 (2019).

    Article 

    Google Scholar
     

  37. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  38. Martens, J. H. A. & Stunnenberg, H. G. BLUEPRINT: mapping human blood cell epigenomes. Haematologica 98, 1487–1489 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  39. Davis, C. A. et al. The Encyclopedia of DNA Elements (ENCODE): data portal update. Nucleic Acids Res. 46, D794–D801 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  40. Mabbott, N. A., Baillie, J. K., Brown, H., Freeman, T. C. & Hume, D. A. An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics 14, 632 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  41. Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  42. Polański, K. et al. BBKNN: fast batch alignment of single cell transcriptomes. Bioinformatics 36, 964–965 (2020).

    Article 
    PubMed 

    Google Scholar
     

  43. Tweedie, S. et al. Genenames.org: the HGNC and VGNC resources in 2021. Nucleic Acids Res. 49, D939–D946 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  44. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580 (2013).

    Article 

    Google Scholar
     

  45. Jiang, L. et al. A quantitative proteome map of the human body. Cell 183, 269–283 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  46. Breiman, L. Random forests. Machine Learning 45, 5–32 (2001).

    Article 

    Google Scholar
     

  47. Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940–3941 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  48. Abadi, M. et al. TensorFlow: a system for large-scale machine learning. Proc. 12th USENIX Symposium on Operating Systems Design and Implementation. https://www.usenix.org/system/files/conference/osdi16/osdi16-abadi.pdf (2016).

  49. Kingma, D. P. & Ba, J. Adam: a method for stochastic optimization. Proc. 3rd International Conference on Learning Representations. https://doi.org/10.48550/arXiv.1412.6980 (2014).

  50. Kwon, J. Integrative single-cell mapping of combinatorial target antigens for logical CAR switches. https://doi.org/10.5281/zenodo.7416669 (2022).

  51. An, H. J. Single cell 5′ RNA sequencing of 9 Korean ovarian cancer patients. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=gse192898 (2023).

  52. omics lab @ KAIST. kaistomics/PCASA: PCASA. https://doi.org/10.5281/zenodo.7514043 (2023).

Download references

Acknowledgements

This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation, funded by the Ministry of Science & ICT (NRF-2017M3A9A7050612, NRF-2019M3A9B6064688, NRF-2019M3A9B6064691 and NRF-2021M3A9I402444711), and also supported by the Korea Health Technology R&D Project of the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare (HI16C1559).

Author information

Author notes

  1. These authors contributed equally: Joonha Kwon, Junho Kang.

Authors and Affiliations

  1. Department of Bio and Brain Engineering, KAIST, Daejeon, Republic of Korea

    Joonha Kwon, Kayoung Seo, Dohyeon An, Jun Hyeong Lee & Jung Kyoon Choi

  2. Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea

    Junho Kang, Mert Yakup Baykan & Jong-Eun Park

  3. Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Areum Jo, Nayoung Kim, Hye Hyeon Eum & Hae-Ock Lee

  4. Department of Biomedicine and Health Sciences, Graduate School, The Catholic University of Korea, Seoul, Republic of Korea

    Areum Jo, Nayoung Kim, Hye Hyeon Eum & Hae-Ock Lee

  5. Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam-si, Republic of Korea

    Sohyun Hwang & Hee Jung An

  6. Department of Biomedical Science, CHA University, Pocheon-si, Republic of Korea

    Sohyun Hwang

  7. CHA Advanced Research Institute, CHA Bundang Medical Center, Seongnam-si, Republic of Korea

    Ji Min Lee

  8. Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea

    Woong-Yang Park

  9. Penta Medix Co., Ltd., Seongnam-si, Republic of Korea

    Jung Kyoon Choi

Contributions

Conceptualization: J. Kwon, J. Kang, J.E.P. and J.K.C. Methodology: J. Kwon, J. Kang, A.J., K.S., D.A., M.Y.B., J.H.L., N.K., H.H.E., J.M.L. and W.Y.P. Investigation: J. Kwon, J. Kang, A.J., K.S., D.A., N.K. and H.H.E. Visualization: J. Kwon, J. Kang and M.Y.B. Funding acquisition: J.K.C. Project administration: H.J.A., J.E.P. and J.K.C. Supervision: S.H., H.J.A., H.O.L., J.E.P. and J.K.C. Writing—original draft: J. Kwon, J. Kang and J.H.L. Writing—review and editing: J. Kwon, J. Kang, J.E.P. and J.K.C.

Corresponding authors

Correspondence to
Hee Jung An, Hae-Ock Lee, Jong-Eun Park or Jung Kyoon Choi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Biotechnology thanks Raphael Gottardo, Peter Linsley and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 UMAP representation of the normal cell atlas overlaid with tumor cells and tumor-infiltrating normal cells from selected tumor datasets.

. a, Same plot as Fig. 1e but with cell-type annotation instead of tissue origin information. b, Same plot as Fig. 1e but showing representative cells selected during tumor cellpreserving subsampling by geometric sketching.

Extended Data Fig. 2 Tumor versus normal differences in ECFs and expression levels.

Differences of ECFs (a) and expression levels (b) between tumor and normal cellsfor surfaceome genes ordered by the FI values from the RF model in selected cancer types.

Extended Data Fig. 3 Comparison of cancer types with expression level and FI for surfaceome genes.

a, Clustering heatmap displaying the expression level of surface antigens according to the cancer type. Five major clusters (C1 ~ C5) of genes were denoted. b, Comparison of the different cancer types based on the correlation of the FI values from the cancer type-specific RF model.

Extended Data Fig. 4 Tumor-specific ECF values of subtype marker genes in BRCA samples for which clinical subtype information was available.

The boxplot shows the ECF status of three markers, containing ERBB2, ESR1, and PGR, for all subtypes (ERpositive: n = 11, HER2-positive: n = 8, HER2 and ER double positive: n = 4, TNBC: n = 12): TNBC, Triple-negative breast cancer; ‘+‘ means ‘positive’. Average values of ECFs for ERBB2, ESR1, and PGR, were 0.33 ± 0.15 (s.d.), 0.68 ± 0.15 (s.d), and 0.29 ± 0.18 (s.d.) in ER-positive subtype while HER2-positive subtype showed 0.86 ± 0.19 (s.d.), 0.18 ± 0.3 (s.d.), and 0.01 ± 0.01 (s.d.), respectively. In the case of HER2+ ER+, average values were 0.47 ± 0.19 (s.d.), 0.25 ± 0.23 (s.d.), and 0.06 ± 0.05 (s.d.), and the TNBC subtype showed 0.24 ± 0.14 (s.d), 0.05 ± 0.12 (s.d.), and 0.05 ± 0.15 (s.d.), for ERBB2, ESR1, and PGR, respectively. Data in the box plot represent the first quartile (25%), median (center), and third quartile (75%) with minimum and maximum values. Black points indicate the outliers.

Source data

Extended Data Fig. 5 Correlation between the CNN weight and ECF of each antigen combination in PAAD, LIHC, NSCLC, CRC, and BRCA.

For each of the pairs, the GradCAM weight returned by the CNN model was mapped to the ECF among tumor cells (blue) and normal cells (red). The Pearson correlation coefficient and two-sided P values are shown at the top. Translucent bands around the regression lines represent the confidence interval (CI) of 95%.

Source data

Extended Data Fig. 6 Comparison of tumor versus normal ECFs according to the CNN weight in PAAD, LIHC, NSCLC, CRC, and BRCA.

Tumor and normal ECFs of the combinations were ordered by their CNN weight. The combinations meeting the ECF criteria (> 70% tumor and < 10% normal) were highlighted in color.

Extended Data Fig. 7 Sample-wise co-expression of selected combinations in OV.

Expression correlations of the OV gene pairs were computed by using pan-cancer TCGA samples (n = 11,768) and GTEx normal samples (n = 17,382). The Pearson correlation coefficient was used.

Source data

Extended Data Fig. 8 Across-sample expression patterns of selected logical CAR switches in PAAD, LIHC, NSCLC, CRC, and BRCA.

Shown are the top 10 gene combinations with the largest CNN weight for each cancer type and each logic switch (AND, OR, and NOT). The heatmap intensity scales with the combinatorial tumor (left) and normal (right) ECF values.

Source data

Extended Data Fig. 9 Additional single-cell epitope analysis results for EPCAM and CD24 in ovarian cancer.

a, Distribution of EPCAM and CD24 protein expression levels broken down by annotated cell type. Log2 fold changes comparing CITE-seq ADT signals from targeting antibodies versus isotype controls were computed and are displayed in each cell type. b, Clustering and cell-type mapping of tumor and tumor-resident normal cells based on the CITE-seq transcriptome. c, Single-cell maps, as in (b), overlaid with mRNA expression levels retrieved from CITEseq. d, Single-cell maps, as in (b), overlaid with protein expression levels retrieved from CITE-seq. e, Single-cell maps, as in (b), overlaid with the mRNA expression status indicating cells with both EPCAM and CD24 (brown), only EPCAM (light blue), only CD24 (light red), or none (gray). f, Single-cell maps, as in (b), overlaid with the epitope expression status indicating cells with both EPCAM and CD24 (brown), only EPCAM (light blue), only CD24 (light red), or none (gray).

Extended Data Fig. 10 Single-cell epitope analysis of validation targets in colorectal cancer.

a, Clustering and cell-type mapping of the tumor and tumor-infiltrating normal cells based on the CITE-seq transcriptome of our pooled CRC samples. b, Single-cell maps, as in (a), overlaid with mRNA expression levels retrieved from the CITE-seq experiments. c, Single-cell maps, as in (b), overlaid with protein expression levels retrieved from the CITE-seq experiments. d, Distribution of protein expression levels broken down by annotated cell type. Log2 fold changes comparing CITE-seq ADT signals from targeting antibodies versus isotype controls were computed and are displayed for each protein in each cell type. e, Cell-by-cell protein expression patterns in the tumor and tumor-resident normal cells for CEACAM5 versus EPCAM, CEACAM5 versus CA4, CEACAM5 versus CPM, and CEACAM5 versus VSIG2. Cells enclosed in the marked zones indicate the expression of both proteins for the AND gating and only one protein (CEACAM5) for the NOT gating.

Supplementary information

Reporting Summary

Supplementary Tables 1–9

Supplementary Table 1: Summary of our cancer cell atlas. Supplementary Table 2: Status of cell types for tumor datasets integrated with normal cell atlas. Supplementary Table 3: Summary of selected tumor datasets of six cancer types. Supplementary Table 4: Performance of RF cell classifier for each cancer type. Supplementary Table 5: RF FI for top 100 genes for each cancer type. Supplementary Table 6: CNN weights calculated by Grad-CAM for each cancer type. Supplementary Table 7: Performance of CNN cell classifier for each cancer type. Supplementary Table 8: Sample-wise co-expression for OV target combinations. Supplementary Table 9: Normal ECF distribution by cell types for OV target combinations.

Source data

About this article

Science & Nature Verify currency and authenticity via CrossMark

Cite this article

Kwon, J., Kang, J., Jo, A. et al. Single-cell mapping of combinatorial target antigens for CAR switches using logic gates.
Nat Biotechnol (2023). https://doi.org/10.1038/s41587-023-01686-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41587-023-01686-y

Read More
Joonha Kwon

Latest

Brendan Sorsby’s football career may rightfully be put on ice after Browns appear uninterested

Bullet point summary by AI Brendan Sorsby's professional football career is in serious jeopardy after a major NFL team publicly distanced themselves from him. Cleveland Browns coach Todd Monken ruled out drafting the Texas Tech QB in the supplemental draft due to his college gambling violations. NFL teams are drawing a hard line on off-field

DeSean Jackson Calls Michael Vick’s Support a “Blessing” After Breakthrough HBCU Season

DeSean Jackson’s appointment as the head coach of the Delaware State Hornets caught college football unawares. But what was even more shocking was how he had a winning season with almost no coaching experience. As he talks about his mind-blowing debut season, Jackson mentions former teammate and current rival Michael Vick as a “blessing.” Watch

‘Don’t Think Anyone Wants To Be In Cleveland:’ Cam Heyward Reacts To Myles Garrett Trade

Cam Heyward’s never directly went up against Myles Garrett, which may be why he “could care less” that the former Cleveland Browns pass rusher is no longer in the division. On his Not Just Football podcast, Heyward reacted to the Browns trading Garrett to the Los Angeles Rams. “I think Aaron [Rodgers]’s definitely happy to

2027 NFL Draft Prospect Interview: Braedon Hellinger, LB, Aurora University

Meet Braedon Hellinger, a 2027 NFL Draft prospect. Discover his journey, passion for football, and personal insights. Name: Braedon Hellinger Position: LB College: Aurora University Height: 6’ 0” Weight: 215 lbs X: @23braedon23 Instagram: @2braedon2 What made you decide you wanted to be a football player? What made me decide to be a football player

Newsletter

Don't miss

Brendan Sorsby’s football career may rightfully be put on ice after Browns appear uninterested

Bullet point summary by AI Brendan Sorsby's professional football career is in serious jeopardy after a major NFL team publicly distanced themselves from him. Cleveland Browns coach Todd Monken ruled out drafting the Texas Tech QB in the supplemental draft due to his college gambling violations. NFL teams are drawing a hard line on off-field

DeSean Jackson Calls Michael Vick’s Support a “Blessing” After Breakthrough HBCU Season

DeSean Jackson’s appointment as the head coach of the Delaware State Hornets caught college football unawares. But what was even more shocking was how he had a winning season with almost no coaching experience. As he talks about his mind-blowing debut season, Jackson mentions former teammate and current rival Michael Vick as a “blessing.” Watch

‘Don’t Think Anyone Wants To Be In Cleveland:’ Cam Heyward Reacts To Myles Garrett Trade

Cam Heyward’s never directly went up against Myles Garrett, which may be why he “could care less” that the former Cleveland Browns pass rusher is no longer in the division. On his Not Just Football podcast, Heyward reacted to the Browns trading Garrett to the Los Angeles Rams. “I think Aaron [Rodgers]’s definitely happy to

2027 NFL Draft Prospect Interview: Braedon Hellinger, LB, Aurora University

Meet Braedon Hellinger, a 2027 NFL Draft prospect. Discover his journey, passion for football, and personal insights. Name: Braedon Hellinger Position: LB College: Aurora University Height: 6’ 0” Weight: 215 lbs X: @23braedon23 Instagram: @2braedon2 What made you decide you wanted to be a football player? What made me decide to be a football player

Badgers Beat Blue Bloods to Land Intriguing CB Prospect from California

Wisconsin football's first official visit weekend is the gift that keeps on giving. Just two days after the Badgers secured commitments from four-star wideout Jai Jones and three-star linebacker Nathan Jones, another high-priority target has pledged to Wisconsin after its first big recruiting weekend of the summer. Three-star cornerback Royalton Allen from Hesperia, California became

Jury acquits 2 business executives of bribing Navy admiral for government contract

A federal jury has acquitted two business executives of charges that they conspired to bribe a retired four-star U.S. Navy admiral, who is now serving a six-year prison sentence for his conviction on corruption charges By MICHAEL KUNZELMAN Associated Press WASHINGTON -- A federal jury has acquitted two business executives of charges that they conspired

US Business Leaders Optimistic About China Cooperation, Emphasize Importance of Chinese Market

© 2026 China Money Network. All Rights Reserved. Disclaimer: The views, opinions, forecasts, and statements made by our hosts and guests are the personal views of those respective individuals and may or may not be either endorsed or accepted by China Money Network Limited or the companies with which these individuals are employed.

Tesla’s Business Has Become Much More Diversified in Just the Past Five Years. Does That Make Its Stock a Better Buy Today?

Key Points Tesla's energy generation and storage segment generated 27% revenue growth last year. The company's non-automotive segments were able to help offset a double-digit decline in auto revenue in 2025. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) is known for its electric vehicles (EVs), and while they